Factor VIII (FVIII) is an important component of blood coagulation as its congenital deficiency
results in life-threatening bleeding. Current prophylactic therapy of the disease (hemophilia …

Acute and chronic liver disease are associated with substantial alterations in the hemostatic
system. Evidence from both experimental and clinical studies suggests that anticoagulants …

Abstract Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability
in hemophilia A patients. Although previous studies have determined that age, body mass …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Quantitative abnormalities in factor VIII (FVIII) and its binding partner, von Willebrand factor
(VWF), are associated with an increased risk of bleeding or thrombosis, and pathways that …

Hemophilia A is an X-linked hereditary disorder that results from deficient coagulation factor
VIII (FVIII) activity, leading to spontaneous bleeding episodes, particularly in joints and …

Terminal sialylation determines the plasma half-life of von Willebrand factor (VWF). A role for
macrophage galactose lectin (MGL) in regulating hyposialylated VWF clearance has …

We have previously identified a novel atherosclerosis quantitative trait locus (QTL), Arch
atherosclerosis 5 (Aath5), on mouse chromosome 10 by three-way QTL analyses between …

Iron physiology is regulated by a complex interplay of extracellular transport systems,
coordinated transcriptional responses, and iron efflux mechanisms. Dysregulation of iron …

Abstract Background Factor VIII (FVIII) pharmacokinetics (PK) in adult hemophilia A
populations are highly variable and have been previously determined to be influenced by …